UNIVEC and Terumo Sign Licensing Agreement for Production of Auto-Disable Syringes.

Business Editors/Health and Medical Writers

FARMINGDALE, N.Y.--(BUSINESS WIRE)--Aug. 17, 2000

The Farmingdale-based UNIVEC Corporation (NASDAQ:UNVC), the internationally recognized maker of auto-disable syringes, has entered into a long term licensing agreement with Terumo Europe N.V. (Belgium) for UNIVEC's proprietary auto-destruct syringe technology. The agreement will enable Terumo to produce auto-destruct syringes that are required by the World Health Organization and its collaborating partners for mass immunization campaigns.

Terumo enters into a licensing agreement with UNIVEC along with purchasing its specially designed equipment to assemble the auto destruct syringes. Other terms of the agreement were not disclosed.

"We are pleased to be in this relationship with one of the world's leading syringe manufacturers and its management team whose members are so committed to their growing market," said Joel Schoenfeld, Chairman of UNIVEC.

"UNIVEC's technology is at the forefront of the industry and we look forward to working closely with Terumo on this project," said Dr. Alan Gold, CEO of UNIVEC.

The UNIVEC technology is for auto-disable syringes that can effectively deliver vaccines in a safer manner than with traditional syringes. The UNIVEC syringe prevents re-use and the needless spread of disease. The devices can deliver predetermined doses from 0.05 to 1cc needed to deliver medication, which may prevent contagious diseases from spreading.

Terumo manufactures and sells a broad range of medical products that contribute to society through healthcare by responding to the needs of health care providers and the people they serve. Terumo began to produce disposable syringes in 1963 - the first produced in Japan - specifically designed for safety.

The management of Terumo knows how important safe medical devices are and how essential it is for present day medicine to avert infections via instruments and to promote the security of both hospital workers and patients.

UNIVEC is world leader in auto-disable syringes and is leading the global move for a conversion to AD-Sy from multi-use syringes which are acknowledged by the World Health Organization to be responsible for the spread of disease to millions of people each year.

Terumo Europe NV is a division of Terumo Corporation - Japan, a global medical technology company that develops, manufactures and markets a broad range of products and services. For the fiscal year ended March 31st, 2000, Terumo Corporation reported total revenue of 171 Billion Yen.

"This is a major step in the direction needed to be taken by the health care industry worldwide. I applaud Terumo for this courageous move and I know it will mean other suppliers worldwide will follow suit," said Schoenfeld.

Statements herein that are not descriptions of historical facts are forward-looking and subject to risk and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in the company's Securities and Exchange filings under "Risk Factors," including risks relating to dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the company's proposed products (such as marketing, safety, regulatory, patent product liability, supply, competition and other risks.)